TrialThe lancet. HIV2026

Safety, antiviral activity, and pharmacokinetics of long-acting injectable cabotegravir-rilpivirine in virologically suppressed adolescents living with HIV-1 (IMPAACT 2017/MOCHA): 48-week results of a multinational, phase 1/2, single-arm study.

Aditya H Gaur et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.